Document:

EX-10.14

 Exhibit 10.14 

April 30, 2019 
 Rekha Hemrajani 

Dear Rekha: 
 This letter is with regard to the separation and
consulting agreement (the “Agreement”) between you and FLX Bio, Inc. (the “Company”) dated March 19, 2019. Under Section 4 of the Agreement, you agreed to repay the Company, within 30 days (i.e., by April 18,
2019), a total of $133,566.95 of principal and accrued interest (the “Loan Amount) owed by you to the Company. 
 On April 18, 2019, you requested
that the Company extend the due date for the Loan Amount and reduce the portion of the Loan Amount to be repaid in cash to $73,004.79 and accept 178,124 of the shares pledged as collateral by The Sanjay Popli & Rekha Hemrajani Revocable
Living Trust in satisfaction the remaining balance of $60,562.16, based on the original $0.34 per share purchase price for such shares. 
 Section 4 of
the Agreement is hereby amended and restated in its entirety as follows: 
 “4. PROMISSORY NOTE.
You entered into a Limited Recourse Promissory Note effective June 15, 2016 by which you became indebted to the Company in the amount of $255,000. The principal amount of the loan under the Promissory Note was reduced on February 13,
2018 in connection with the repurchase by the Company from The Sanjay Popli & Rekha Hemrajani Revocable Living Trust of 50,000 shares of common stock of the Company and on March 19, 2019 in connection with the repurchase by the Company
from The Sanjay Popli & Rekha Hemrajani Revocable Living Trust of 321,876 shares of common stock of the Company. The Company agrees to reduce the amount of accrued interest payable by you under the Promissory Note by $4,669.15 (the
“Interest Reduction Amount”). You acknowledge and agree that the Interest Reduction Amount will be a taxable benefit paid by the Company to you. After taking into account the Interest Reduction Amount, the amount of principal and accrued
interest outstanding on the loan as of the Separation Date is $133,566.95 (the “Outstanding Loan Amount”). Pursuant to the Promissory Note, you must repay the outstanding principal amount of the loan, plus interest, immediately upon your
voluntary termination of services to the Company. You acknowledge that you are voluntarily terminating your services to the Company as of the Separation Date and agree to satisfy in full the Outstanding Loan Amount by (a) paying $73,004.79 in
cash to the Company by May 3, 2019 and causing the transfer to the Company of 178,124 of the shares pledged as collateral by The Sanjay Popli & Rekha Hemrajani Revocable Living Trust.” 

  
 1 

 If the foregoing is acceptable to you, please sign below, cause the execution of the enclosed stock powers
on behalf of the The Sanjay Popli & Rekha Hemrajani Revocable Living Trust and return the originals to me. 
 Sincerely, 

 

			
	By:	 	 /s/ Brian Wong

		 	Brian Wong, M.D., Ph.D.
		 	Chief Executive Officer

 I HAVE READ, UNDERSTAND AND AGREE
FULLY TO THE FOREGOING AGREEMENT: 
  

			
	/s/ Rekha Hemrajani                	  	April 30, 2019
	Rekha Hemrajani	  	Date

  
 2EX-10.15

 Exhibit 10.15 

November 15, 2016 
 Linda Kozick 

Dear Linda: 
 The Board of Directors (the “ Board”) of
FLX Bio, Inc. (the “Company”) is pleased to welcome you as a member of the Board. We appreciate your willingness to accept this position, and we look forward to your valuable contributions. 

In connection with your services to the Company, we will pay you the following: 
  

	 	•	 	 Cash Retainer: An annual cash retainer of $20,000, payable in quarterly installments. The retainer will be
subject to adjustment pursuant to the Company’s director compensation policies in effect from time to time. 

  

	 	•	 	 Stock Options: Subject to the terms and conditions of the Company’s 2015 Stock Option Plan and the
applicable stock option agreement, you will be granted an option to purchase 100,000 of the company’s Common Stock (the “Initial Grant”). You will vest in 25% of the Initial Grant after 12 months, and the balance will vest in equal
monthly installments over the next 36 months, as described in the applicable Stock Option Agreement. The Board will also grant you an additional 25,000 shares per year (the “Annual Grant”) starting at your second anniversary of Board
service. The Annual Grants will vest in equal monthly installments over 48 months. The exercise price per share of the Initial Grant and the Annual Grants will be equal to the fair market value per share on the date the option is granted, and the
options will be early exercisable. In addition, if FLX Bio is subject to a Change of Control, then the Company shall accelerate the vesting of your Stock Options such that 100% of your Stock Options shall become fully vested. 

We will review our compensation policy for Board members in the event of an initial public offering. 

We will also reimburse you for reasonable expenses that you incur in connection with attendance at meetings of the Board, or committees of the Board, in
accordance with the Company’s generally applicable reimbursement policies. 
 In connection with your services to the Company, we expect that
technical, business or financial information of the Company (“Confidential Information”) will be disclosed to you. To the extent that Confidential Information is not publicly known or not otherwise previously known by you without an
obligation of confidentiality, you agree not to use (except in connection with your services to the Company) or disclose Confidential Information to any third party and to take reasonable steps to maintain the confidential nature of all Confidential
Information. By signing this letter agreement, you represent and warrant that you have no contractual commitments or other legal obligations to a third party that would prohibit you from performing your duties for the Company. 

 As part of your overall responsibilities, the Company and the Company’s stockholders reserve the right
to remove any individual from the Board at any time in accordance with the provisions of applicable law. You, of course, may also terminate your relationship with the Company at any time. When you cease to be a member of the Board (whether at our
request or your election), you must return all Confidential Information of the Company. 
 On behalf of the full Board, we are excited about your joining
our Board and look forward to working with you to help make the Company truly great and prosperous. You may indicate your agreement with these terms and accept this offer by signing and dating the enclosed duplicate original of this letter agreement
and returning to me. 
 If you have any questions, please do not hesitate to call me. 

 

	
	Very truly yours,
	
	FLX Bio, Inc.
	
	 /s/ Brian Wong

	Brian Wong, M.D. Ph.D., Chief Executive Officer

  

	
	I have read and accept this offer:
	
	 /s/ Linda Kozick

	Signature of Linda Kozick
	
	Dated: 11/21/16EX-10.16

 Exhibit 10.16 

 
 

 
 January 12, 2018 

Dr. Michael F. Giordano, M.D. 
 Dear Michael: 

The Board of Directors (the “Board”) of FLX Bio, Inc. (the “Company”) is pleased to welcome you as a member of the Board. We appreciate
your willingness to accept this position, and we look forward to your valuable contributions. 
 In connection with your services to the Company, we will
pay you the following: 
  

	 	•	 	 Cash Retainer: An annual cash retainer of $20,000, payable in quarterly installments. The retainer will be
subject to adjustment pursuant to the Company’s director compensation policies in effect from time to time. 

  

	 	•	 	 Stock Options: Subject to the terms and conditions of the Company’s 2015 Stock Option Plan and the
applicable stock option agreement, you will be granted an option to purchase 100,000 of the company’s Common Stock (the “Initial Grant”). You will vest in equal monthly installments over the next 48 months, as described in the
applicable Stock Option Agreement. The Board will also grant you an additional 25,000 shares per year (the “Annual Grant”) starting at your second anniversary of Board service. The Annual Grants will vest in equal monthly installments over
48 months. The exercise price per share of the Initial Grant and the Annual Grants will be equal to the fair market value per share on the date the option is granted, and the options will be early exercisable. In addition, if FLX Bio is subject to a
Change of Control, then the Company shall accelerate the vesting of your Stock Options such that 100% of your Stock Options shall become fully vested. 

We will review our compensation policy for Board members in the event of an initial public offering. 

We will also reimburse you for reasonable expenses that you incur in connection with attendance at meetings of the Board, or committees of the Board, in
accordance with the Company’s generally applicable reimbursement policies. 
 FLX Bio, Inc.; 561 Eccles Avenue, South San Francisco, CA
94080 

 In connection with your services to the Company, we expect that technical, business or financial information
of the Company (“Confidential Information”) will be disclosed to you. To the extent that Confidential Information is not publicly known or not otherwise previously known by you without an obligation of confidentiality, you agree not to use
(except in connection with your services to the Company) or disclose Confidential Information to any third party and to take necessary and reasonable steps to maintain the confidential nature of all Confidential Information. By signing this letter
agreement, you represent and warrant that you have no contractual commitments or other legal obligations to a third party that would prohibit you from performing your duties for the Company. 

As part of your overall responsibilities, the Company and the Company’s stockholders reserve the right to remove any individual from the Board at any
time in accordance with the provisions of applicable law. You, of course, may also terminate your relationship with the Company at any time. When you cease to be a member of the Board (whether at our request or your election), you must return all
Confidential Information of the Company. 
 On behalf of the full Board, we are excited about your joining our Board and look forward to working with you to
help make the Company truly great and prosperous. You may indicate your agreement with these terms and accept this offer by signing and dating the enclosed duplicate original of this letter agreement and returning it to me. 

If you have any questions, please do not hesitate to call me. 
  

	
	Very truly yours,
	
	FLX Bio, Inc.
	
	 /s/ Brian R. Wong

	Brian R. Wong, M.D., Ph.D.
	Chief Executive Officer

  

			
	I have read and accept this offer:
	
	 /s/ Michael F. Giordano

	Signature of Michael F. Giordano, M.D.
		
	Dated:	 	1/19/18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}]]